Literature DB >> 25895984

Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.

Monica Gandhi1, David V Glidden2, Albert Liu3, Peter L Anderson4, Howard Horng5, Patricia Defechereux6, Juan V Guanira7, Beatriz Grinsztejn8, Suwat Chariyalertsak9, Linda-Gail Bekker10, Robert M Grant11.   

Abstract

Self-reported adherence to pre-exposure prophylaxis (PrEP) has limitations, raising interest in pharmacologic monitoring. Drug concentrations in hair and dried blood spots (DBS) are used to assess long-term-exposure; hair shipment/storage occurs at room temperature. The iPrEx Open Label Extension collected DBS routinely, with opt-in hair collection; concentrations were measured with liquid chromatography/tandem mass spectrometry. In 806 hair-DBS pairs, tenofovir (TFV) hair levels and TFV diphosphate (DP) in DBS were strongly correlated (Spearman coefficient r = 0.734; P < .001), as were hair TFV/DBS emtricitabine (FTC) triphosphate (TP) (r = 0.781; P < .001); hair FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001). Drug detectability was generally concordant by matrix. Hair TFV/FTC concentrations correlate strongly with DBS levels, which are predictive of PrEP outcomes.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV prevention; PrEP; adherence; dried blood spot (DBS) concentrations; hair concentrations; iPrEx Open Label Extension (OLE); pharmacologic monitoring; pre-exposure prophylaxis; tenofovir/emtricitabine

Mesh:

Substances:

Year:  2015        PMID: 25895984      PMCID: PMC4601920          DOI: 10.1093/infdis/jiv239

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.

Authors:  Monica Gandhi; Qiyun Yang; Peter Bacchetti; Yong Huang
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

2.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

3.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

4.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

7.  "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

Authors:  Thomas J Podsadecki; Bernard C Vrijens; Eric P Tousset; Richard A Rode; George J Hanna
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures.

Authors:  Sanjiv M Baxi; Albert Liu; Peter Bacchetti; Gaudensia Mutua; Eduard J Sanders; Freddie M Kibengo; Jessica E Haberer; James Rooney; Craig W Hendrix; Peter L Anderson; Yong Huang; Frances Priddy; Monica Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

10.  HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Authors:  Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

View more
  40 in total

1.  Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.

Authors:  Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain
Journal:  Int J Infect Dis       Date:  2020-06-14       Impact factor: 3.623

2.  Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Authors:  Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

3.  Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Authors:  Sharon M Seifert; Jose R Castillo-Mancilla; Kristine Erlandson; Mary Morrow; Monica Gandhi; Karen Kuncze; Howard Horng; Jia-Hua Zheng; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

4.  Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function.

Authors:  Jose Carlo Hojilla; Derek D Satre; David V Glidden; Vanessa M McMahan; Monica Gandhi; Patricia Defechereux; Juan V Guanira; Megha Mehrotra; Robert M Grant; Adam W Carrico
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

5.  Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Authors:  Monica Gandhi; David V Glidden; Kenneth Mayer; Mauro Schechter; Susan Buchbinder; Beatriz Grinsztejn; Sybil Hosek; Martin Casapia; Juan Guanira; Linda-Gail Bekker; Alexander Louie; Howard Horng; Leslie Z Benet; Albert Liu; Robert M Grant
Journal:  Lancet HIV       Date:  2016-08-31       Impact factor: 12.767

Review 6.  Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.

Authors:  Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

7.  Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.

Authors:  Jillian Pintye; John Kinuthia; Felix Abuna; Kenneth Mugwanya; Harison Lagat; Julia C Dettinger; Daniel Odinga; Joseph Sila; Peter L Anderson; Grace John-Stewart; Jared M Baeten
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

8.  Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.

Authors:  David J Moore; Sonia Jain; Michael P Dubé; Eric S Daar; Xiaoying Sun; Jason Young; Katya Corado; Eric Ellorin; Joel Milam; Deborah Collins; Jill Blumenthal; Brookie M Best; Peter Anderson; Richard Haubrich; Sheldon R Morris
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

9.  Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.

Authors:  Matthew A Spinelli; David V Glidden; Warren C Rodrigues; Guohong Wang; Michael Vincent; Hideaki Okochi; Karen Kuncze; Megha Mehrotra; Patricia Defechereux; Susan P Buchbinder; Robert M Grant; Monica Gandhi
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

10.  Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.

Authors:  Jon W Collins; J Heyward Hull; Julie B Dumond
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.